Apollo Endosurgery, Inc. (NASDAQ:APEN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Inc. (the Company) approved its 2017 Bonus Plan in which the
Chief Executive Officer, as well as the Chief Financial Officer
and certain other named executive officers will participate (the
2017 >Bonus Plan).
Todd Newton, is eligible to receive a target bonus of $200,000;
our Chief Financial Officer, Stefanie Cavanaugh, is eligible to
receive a target bonus of $88,007; our President and Chief
Commercial Officer, Dennis McWilliams is eligible to receive a
target bonus of $140,000, and our Executive Vice President of
Operations, Charles Tribi, is eligible to receive a target bonus
of $99,750.
entirety by the terms set forth in the 2017 Bonus Plan attached
hereto as Exhibit 10.1.
|
Exhibit No.
|
Description of Document
|
|
|
10.1
|
2017 Bonus Plan
|
About Apollo Endosurgery, Inc. (NASDAQ:APEN)
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract. Apollo Endosurgery, Inc. (NASDAQ:APEN) Recent Trading Information
Apollo Endosurgery, Inc. (NASDAQ:APEN) closed its last trading session down -0.58 at 6.18 with 16,149 shares trading hands.
